Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity - eBioMedicine
Por um escritor misterioso
Descrição
Tumor-targeted CD28 bispecific antibodies enhance the antitumor efficacy of PD-1 immunotherapy
Frontiers Progress in construction of mouse models to investigate the pathogenesis and immune therapy of human hematological malignancy
IJMS, Free Full-Text
Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity - eBioMedicine
Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity - eBioMedicine
Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab. - Abstract - Europe PMC
Biomedicines, Free Full-Text
IFN-γ independent markers of Mycobacterium tuberculosis exposure among male South African gold miners - eBioMedicine
Anti-Multiple Myeloma Activity of Nanobody-Based Anti-CD38 Chimeric Antigen Receptor T Cells
IFN-γ independent markers of Mycobacterium tuberculosis exposure among male South African gold miners - eBioMedicine
AAV-CRISPR-Cas13 eliminates human enterovirus and prevents death of infected mice - eBioMedicine
Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab. - Abstract - Europe PMC
PDF) Potent preclinical activity of HexaBody-DR5/DR5 in relapsed and/or refractory multiple myeloma
Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma. - Abstract - Europe PMC
de
por adulto (o preço varia de acordo com o tamanho do grupo)
